When genes are expressed at the wrong time or in the wrong amounts, it alters the function of a cell, leading to disease. By developing small-molecule medicines to control the expression of genes, we aim to make a profound difference in patients’ lives. We are advancing a growing pipeline of investigational gene control medicines for diseases that have largely eluded other genomics-based approaches. Our current focus is on cancer and monogenic diseases.
| Program | Indication | Target Development | Drug Discovery | IND-Enabling | Early Clinical | Mid Clinical | Pivotal | Commercial Rights |
|---|---|---|---|---|---|---|---|---|
SY-1425 (RARα agonist) |
SY-1425 (RARα agonist)
Frontline AML (combination with azacitidine) |
Target Development Phase complete
|
Drug Discovery Phase complete
|
IND-Enabling Phase complete
|
Early Clinical Phase complete
|
Mid Clinical Phase in progress
|
Pivotal Phase not started
Syros (North America & Europe)
|
Syros (North America & Europe) |
|
SY-1425 (RARα agonist)
Relapsed or refractory AML (combination with azacitidine) |
Target Development Phase complete
|
Drug Discovery Phase complete
|
IND-Enabling Phase complete
|
Early Clinical Phase complete
|
Mid Clinical Phase in progress
|
Pivotal Phase not started
Syros (North America & Europe)
|
||
SY-5609 (Oral CDK7 inhibitor) |
SY-5609 (Oral CDK7 inhibitor)
Cancer |
Target Development Phase complete
|
Drug Discovery Phase complete
|
IND-Enabling Phase in progress
|
Early Clinical Phase not started
|
Mid Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
CDK12/13 Inhibitor |
CDK12/13 Inhibitor
Cancer |
Target Development Phase complete
|
Drug Discovery Phase in progress
|
IND-Enabling Phase not started
|
Early Clinical Phase not started
|
Mid Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
Macrophage Target |
Macrophage Target
Cancer/immune modulation |
Target Development Phase complete
|
Drug Discovery Phase in progress
|
IND-Enabling Phase not started
|
Early Clinical Phase not started
|
Mid Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
LRF & NuRD modulators |
LRF & NuRD modulators
Sickle cell disease/beta thalassemia |
Target Development Phase complete
|
Drug Discovery Phase in progress
|
IND-Enabling Phase not started
|
Early Clinical Phase not started
|
Mid Clinical Phase not started
|
Pivotal Phase not started
GBT (Global; Syros US co-promote option)
|
GBT (Global; Syros US co-promote option) |
Triplet repeat modulator |
Triplet repeat modulator
Myotonic dystrophy type 1 |
Target Development Phase complete
|
Drug Discovery Phase in progress
|
IND-Enabling Phase not started
|
Early Clinical Phase not started
|
Mid Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
Discovery |
Discovery
Cancer |
Target Development Phase in progress
|
Drug Discovery Phase not started
|
IND-Enabling Phase not started
|
Early Clinical Phase not started
|
Mid Clinical Phase not started
|
Pivotal Phase not started
Syros (Global)
|
Syros (Global) |
Discovery |
Discovery
Myeloproliferative neoplasms |
Target Development Phase in progress
|
Drug Discovery Phase not started
|
IND-Enabling Phase not started
|
Early Clinical Phase not started
|
Mid Clinical Phase not started
|
Pivotal Phase not started
Incyte (Global)
|
Incyte (Global) |
Dan AML Patient
SY-1425
Our lead drug candidate, SY-1425, is a first-in-class selective oral retinoid acid receptor alpha (RARα) agonist in a Phase 2 clinical trial in a genomically defined subset of patients with acute myeloid leukemia.
View Program
Anne Ovarian Cancer Survivor
SY-5609
Our second most advanced program, SY-5609, is highly selective and potent oral cyclin-dependent kinase 7 (CDK7) expected to enter a Phase 1 trial in the first quarter of 2020 in patients with select solid tumors, breast, lung and ovarian cancers, as well as solid tumors of any histology with a specific molecular signature.
View Program